Cooper Companies (COO)
NASDAQ:COO
Want to see COO full AI Analyst Report?
Top Page
Cooper Co
(NASDAQ:COO)
Select Model
Select Model
Rating:57Neutral
Price Target:
$70.00
▼(-0.09% Downside)
Action:Reiterated
Date:06/06/26
The score is driven primarily by solid underlying business stability (growth and a strong balance sheet) but tempered by a recent deterioration in margins and free-cash-flow strength. The latest earnings call supports the outlook with reaffirmed growth and improved FCF targets, yet near-term headwinds (litigation-related cash demands, APAC weakness, and margin pressure) keep the score in the mid-range. Technically, momentum is mixed and the valuation is expensive (high P/E), which further limits upside in the overall rating.
Positive Factors
Market Leadership - CooperVision
Leading market share in contact lenses (about one-third of wearers) gives durable scale advantages: broader distribution, stronger negotiating power with suppliers and customers, recurring consumable revenue, and higher product-awareness barriers for competitors, supporting steady revenue and pricing resilience over time.
Negative Factors
Eroding Profitability
Material margin erosion year-over-year indicates weaker earnings quality and less cushion against cost shocks. Persistently lower net margins reduce return on equity and free cash flow conversion, limiting reinvestment capacity and making long-term EPS growth more dependent on volume gains or structural cost improvements.
Read all positive and negative factors
Positive Factors
Negative Factors
Market Leadership - CooperVision
Leading market share in contact lenses (about one-third of wearers) gives durable scale advantages: broader distribution, stronger negotiating power with suppliers and customers, recurring consumable revenue, and higher product-awareness barriers for competitors, supporting steady revenue and pricing resilience over time.
Read all positive factors
Cooper Co Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows how different parts of the business contribute to overall sales, highlighting strengths and potential areas for growth within the company's diverse operations.
Shows how different parts of the business contribute to overall sales, highlighting strengths and potential areas for growth within the company's diverse operations.
Data provided by:
The Fly
The FlyCooper Co (COO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.22B
Dividend YieldN/A
Average Volume (3M)3.16M
Price to Earnings (P/E)55.7
Beta (1Y)0.57
Revenue Growth6.09%
EPS Growth-42.65%
CountryUS
Employees16,000
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)1.18
Shares Outstanding195,030,620
10 Day Avg. Volume4,355,523
30 Day Avg. Volume3,158,991
Financial Highlights & Ratios
PEG Ratio-8.16
Price to Book (P/B)1.70
Price to Sales (P/S)3.42
P/FCF Ratio32.24
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue3.65
Enterprise Value/Gross Profit5.68
Enterprise Value/Ebitda17.85
Forecast
1Y Price Target
$79.70Price Target Upside13.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)4.63
Revenue Forecast (FY)$4.31B
Cooper Co Business Overview & Revenue Model
Company Description
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in cont...
How the Company Makes Money
Cooper Co. generates revenue primarily by designing, manufacturing, and selling advanced medical products through its two main operating segments. CooperVision drives income by offering a broad portfolio of contact lenses, catering to various visi...
Cooper Co Earnings Call Summary
Earnings Call Date:Jun 04, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Sep 02, 2026
Earnings Call Sentiment Positive
The call presents a generally positive operational and financial picture: record quarterly revenue and strong non-GAAP EPS, meaningful margin expansion, robust product-level growth (notably MiSight and CooperSurgical fertility), improved free cash flow and active strategic initiatives. However, material near-term headwinds create caution — a significant litigation settlement affecting GAAP results and concentrated cash outflows, Asia Pacific market softness tied to legacy product rationalization and consumer weakness (especially Japan/China), and expected short-term gross margin pressure from FX, tariffs and inventory optimization. Management balanced conservative guidance with a clear plan for capital allocation and strategic review progress, leaving the near-term outlook mixed but supported by strong execution and long-term cash-generation targets.Positive Updates
Record Quarterly Revenue and Earnings
Consolidated revenue of $1.08 billion, up 8% year-over-year; non-GAAP EPS of $1.21, up 26% year-over-year; tenth consecutive quarter beating consensus.
Negative Updates
Significant Litigation Charge in Fertility Business
Net accrual to resolve outstanding claims of $271.6 million (accrued settlements $324.1M offset by $52.5M insurance recoveries); charge excluded from non-GAAP results but materially affects GAAP results and expected payouts concentrated in fiscal 2026.
Read all updates
Q2-2026 Updates
Positive
Negative
Record Quarterly Revenue and Earnings
Consolidated revenue of $1.08 billion, up 8% year-over-year; non-GAAP EPS of $1.21, up 26% year-over-year; tenth consecutive quarter beating consensus.
Read all positive updates
Company Guidance
Cooper guided fiscal 2026 revenue of roughly $4.28–$4.32 billion (up 5–6% YoY; organic growth 3.5–4.5%), with CooperVision revenue targeted at about $2.88–$2.91 billion (also +5–6% / +3.5–4.5% organic) and CooperSurgical roughly $1.40–$1.41 billion (+4–5% reported; ~unchanged organically), non‑GAAP EPS of $4.58–$4.66, interest expense of about $85 million, an effective tax rate of ~15.5%, and 2026 free cash flow of roughly $650 million (excluding litigation payouts) while reaffirming a $2.2 billion free‑cash‑flow goal for 2026–2028; they expect full‑year gross margins to decline with Q3 gross margin near ~66%, assume ~$22 million of tariffs (possible refunds up to ~$15 million), do not bake in buyback accretion, and excluded a $271.6 million net litigation settlement from non‑GAAP results.Cooper Co Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
74
Positive
Cash Flow
48
Neutral
| Breakdown | TTM | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.23B | 4.09B | 3.90B | 3.59B | 3.31B | 2.92B |
| Gross Profit | 2.72B | 2.48B | 2.60B | 2.36B | 2.14B | 1.96B |
| EBITDA | 865.90M | 1.05B | 1.07B | 885.90M | 878.70M | 823.90M |
| Net Income | 235.80M | 374.90M | 392.30M | 294.20M | 385.80M | 2.94B |
Balance Sheet | ||||||
| Total Assets | 12.48B | 12.39B | 12.32B | 11.66B | 11.49B | 9.61B |
| Cash, Cash Equivalents and Short-Term Investments | 138.80M | 110.60M | 107.60M | 120.90M | 138.20M | 95.90M |
| Total Debt | 2.46B | 2.78B | 2.58B | 2.57B | 2.76B | 1.48B |
| Total Liabilities | 4.24B | 4.16B | 4.23B | 4.11B | 4.32B | 2.66B |
| Stockholders Equity | 8.24B | 8.24B | 8.08B | 7.55B | 7.17B | 6.94B |
Cash Flow | ||||||
| Free Cash Flow | 569.50M | 433.70M | 288.10M | 215.00M | 450.40M | 524.20M |
| Operating Cash Flow | 953.00M | 796.10M | 709.30M | 607.50M | 692.40M | 738.60M |
| Investing Cash Flow | -389.80M | -372.90M | -764.60M | -449.00M | -1.83B | -450.30M |
| Financing Cash Flow | -544.40M | -425.90M | 39.20M | -173.90M | 1.19B | -311.40M |
Cooper Co Technical Analysis
Neutral
70.06
Price Trends
64.50
Positive
71.07
Negative
72.67
Negative
Market Momentum
1.25
Negative
61.51
Neutral
84.87
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COO, the sentiment is Neutral. The current price of 70.06 is above the 20-day moving average (MA) of 63.83, above the 50-day MA of 64.50, and below the 200-day MA of 72.67, indicating a neutral trend. The MACD of 1.25 indicates Negative momentum. The RSI at 61.51 is Neutral, neither overbought nor oversold. The STOCH value of 84.87 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for COO.
Cooper Co Risk Analysis
Cooper Co disclosed 40 risk factors in its most recent earnings report. Cooper Co reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cooper Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $23.41B | 43.73 | 17.87% | 0.32% | 11.24% | 17.11% | |
64 Neutral | $9.42B | 123.11 | 9.08% | ― | -21.03% | ― | |
57 Neutral | $13.22B | 55.70 | 2.84% | ― | 6.09% | -42.65% | |
55 Neutral | $7.54B | 19.99 | 14.33% | 1.50% | 8.95% | 6.13% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $10.75B | -9.60 | -16.43% | 2.75% | -4.79% | -78.01% |
* Healthcare Sector Average
COO
Cooper Co
67.35
-1.41
-2.05%
ATR
AptarGroup
120.65
-26.68
-18.11%
BAX
Baxter International
20.46
-9.20
-31.03%
MASI
Masimo
179.95
20.63
12.95%
WST
West Pharmaceutical Services
329.58
112.24
51.64%
Cooper Co Corporate Events
Business Operations and StrategyExecutive/Board Changes
CooperCompanies Adds Paul Keel to Board of Directors
Positive
May 4, 2026
CooperCompanies said on May 4, 2026, that its board has appointed Paul Keel as an independent director, effective July 1, 2026. He will also join the Audit Committee, adding high-level financial oversight experience to the board’s governance...
Executive/Board ChangesShareholder Meetings
Cooper Co Stockholders Approve Directors, Auditor and Pay
Positive
Apr 8, 2026
On April 7, 2026, The Cooper Companies, Inc. held its 2026 Annual Meeting of Stockholders, at which stockholders elected nine directors, including Colleen E. Jay, Barbara A. Carbone, and Albert G. White III, to serve until the 2027 annual meeting ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.